Pfizer Corporation

Pharmacia Italia S.p.a.

Mats Dahlberg

Anders Berkenstam

Arturo Galvani

Jurgen Moll

The present invention relates to novel vitamin D receptor related (VDRR) polypeptides, and formulations containing the same. Nucleic acid sequences encoding the VDRR polypeptides, expression vectors containing such sequences and host cells transformed with such expression vectors are also disclosed, as are methods for the expression of the novel VDRR polypeptides of the invention. The invention further relates to VDRR polypeptides for use as medicaments, and use of substances affecting VDRR signal transduction for the manufacture of medicaments for treating metabolic, proliferative or inflammatory conditions. The present invention also relates to methods for identifying clones encoding a VDRR polypeptide, methods for identifying ligands to a VDRR and methods for identifying substances for treatment of conditions affected by a VDRR polypeptide. More specifically, the novel VDRR polypeptide can be the polypeptide designated VDRR&#x3b3;, which may be regulated by any small chemical molecule similar in structure to known ligands for nuclear receptors.

Nucleic acid encoding vitamin D receptor related polypeptide

The present invention provides a human polypeptide homolog of P-activated kinase (PAK) polynucleotides which identify and encode PAKserine/threonine kinase. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of PAKagonists/antagonists, useful for the treatment of human diseases and conditions.

Growing community of inventors

Stockholm, Sweden

Mats Dahlberg